Why Are Haemonetics (HAE) Shares Soaring Today

Core Insights - Haemonetics shares surged 22.1% following the release of third-quarter results that exceeded analyst expectations and an upward revision of full-year financial guidance [1][2] Financial Performance - The company reported adjusted earnings of $1.27 per share on revenue of $327.3 million, both surpassing Wall Street forecasts [2] - Total revenue declined 5.3% year-on-year, but organic revenue fell only 1.8%, indicating resilience in core operations [2] - Operating margin improved to 17.9% from 15% in the same quarter last year, and free cash flow reached $106.3 million [2] - Management raised full-year adjusted earnings per share guidance to a midpoint of $4.90 [2] Market Reaction - Haemonetics shares are characterized by low volatility, with only 8 moves greater than 5% in the past year, suggesting significant market impact from recent news [4] - The stock has experienced a decline of 16.9% since the beginning of the year and is currently trading 30.2% below its 52-week high of $93.38 [6]